Skip to content
E2 · Observational studyCohortPEM requiredObservationalPeer-reviewed
Standard · 3 min

Low-dose rapamycin alleviates clinical symptoms of fatigue and PEM in ME/CFS patients via improvement of autophagy: a pilot study.

Ruan, Brian T, Bulbule, Sarojini, Gile, Brooke et al.

Journal of translational medicine2025DOIPubMed

Design
Observational
Participants
Not reported
PEM required
Yes
Case definition
Not stated in the abstract

Quick Summary

Researchers tested a low-dose drug called rapamycin in 86 ME/CFS patients to see if it could reduce fatigue and post-exertional malaise (PEM). About 74% of patients who completed the first month showed improvements in fatigue, PEM, and other symptoms, and the drug appeared safe with no serious side effects. The study suggests that rapamycin may work by fixing a cellular process called autophagy, which appears to be broken in ME/CFS patients.

Why It Matters

This study provides evidence that a targetable biological mechanism—mTOR-mediated autophagy disruption—may drive ME/CFS symptoms, opening a potential therapeutic pathway. The safety profile and symptom improvements suggest rapamycin warrants further investigation in controlled trials, potentially offering the first disease-modifying treatment for ME/CFS.

Observed Findings

What the study reports it measured.

  • 74.3% of completers (52/70) showed recovery in fatigue, PEM, and orthostatic intolerance by day 30, with sustained improvements through day 90
  • Plasma pSer258-ATG13 levels were significantly downregulated at day 30 (T1)
  • Plasma BECLIN-1 levels were elevated at day 90 (T3)
  • Rapamycin at 6 mg/week was tolerated with no serious adverse events reported
  • Spearman correlation analysis showed association between autophagy impairment markers and reduced activity levels

Inferred Conclusions

What the authors interpret from those results.

  • Low-dose rapamycin improves core ME/CFS symptoms (fatigue, PEM, OI) via enhancement of autophagy pathways
  • mTOR inhibition may be a viable therapeutic strategy for autophagy-disruption subtypes of ME/CFS
  • Autophagy biomarkers (pSer258-ATG13, BECLIN-1) correlate with clinical symptom improvement and may reflect mechanistic action
  • Future work should identify patient subgroups with mTOR-mediated autophagy dysfunction to enable precision treatment

Remaining Questions

  • What is the optimal rapamycin dose, and how does it balance efficacy against long-term safety concerns?
  • Which baseline biological or clinical characteristics predict treatment response, and can these be used to identify good candidates?
  • Does rapamycin's benefit persist beyond 90 days, and what happens when treatment is discontinued?
  • How does rapamycin compare to standard care or placebo in a randomized controlled trial?

What This Study Does Not Prove

This study does not prove rapamycin is effective, as it lacks a control group and placebo comparison; observed improvements could reflect natural variation, placebo effect, or regression to the mean. It does not establish that autophagy dysfunction is the primary cause of ME/CFS, only that it may be associated with symptoms in some patients. The study cannot identify which patients will respond, as no baseline predictive markers were validated.

Explore further

About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →

Cite this study

The first block is for the primary paper and is the citation you should use in research work. The atlas-snapshot line only applies if you are specifically referring to this atlas’s reading of the paper on the date shown.

Primary citation

Ruan, Brian T, Bulbule, Sarojini, Gile, Brooke, Reyes, Amy, Chheda, Bela, Bateman, Lucinda, et al. (2025). Low-dose rapamycin alleviates clinical symptoms of fatigue and PEM in ME/CFS patients via improvement of autophagy: a pilot study.. Journal of translational medicine. https://doi.org/10.1186/s12967-025-07213-8

BibTeX

@article{mecfsatlas-ruan-2025-low-dose-2,
  author  = {Ruan, Brian T and Bulbule, Sarojini and Gile, Brooke and Reyes, Amy and Chheda, Bela and Bateman, Lucinda and Bell, Jennifer and Yellman, Brayden and Grach, Stephanie L and Berner, Jon and Peterson, Daniel L and Kaufman, David and Roy, Avik and Gottschalk, C Gunnar},
  title   = {Low-dose rapamycin alleviates clinical symptoms of fatigue and PEM in ME/CFS patients via improvement of autophagy: a pilot study.},
  journal = {Journal of translational medicine},
  year    = {2025},
  doi     = {10.1186/s12967-025-07213-8},
  note    = {PubMed: 41121328},
  url     = {https://www.mecfsatlas.com/evidence/ruan-2025-low-dose-2},
}

Atlas snapshot reference

ME/CFS Atlas. Generator v1 / Scanner v1.4 / policy v0.1. Accessed 2026-11-14. https://www.mecfsatlas.com/evidence/ruan-2025-low-dose-2

Contribute

Private, reviewed by a human. Not a public comment thread.